Neumora Therapeutics will discontinue its lead depression drug after two Phase 3 failures and lay off about 35% of its employees.
The Really Big Neuroscience Company is proving to be a Really Big Flop with each passing update.
Neumora Therapeutics will discontinue its lead depression drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing…
A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout
On Monday, Praxis disclosed a late-stage failure for its investigational seizure medicine, and the company is pausing enrollment…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions attributed…
